Valeant says Philidor pharmacy shutting down as it cuts ties
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
Margin Pressures Could Weigh on CVS Health (CVS) Shares; Oppenheimer Cuts Price Target to $115
November 2, 2015 11:16 AM ESTOppenheimer maintained an Outperform rating on CVS Health (NYSE: CVS), and cut the price target to $115.00 (from $122.00), following the company's 3Q earnings results. CVS reported 3Q revenue of $38.6B vs. consensus $37.9B. Adj. EPS was $1.29, in line with consensus $1.29. Analyst Mohan Naidu believes that the margin outlook and lack of clarity on organic growth in... More
Leerink Partners Would Buy CVS Health (CVS) on Current Weakness
October 30, 2015 1:39 PM EDTLeerink Partners reiterated an Outperform rating and $125.00 price target on CVS Health (NYSE: CVS) following the company's 3Q earnings and conference call. Management highlighted that the core business continues to grow at a healthy rate. While 2016E EPS guidance is below consensus expectations, management reiterated that their longterm adjusted EPS growth... More
Bill Ackman said Valeant Pharma (VRX) worth $180-$240 Near-Term, $262-$350 Long-Term
October 30, 2015 10:14 AM EDTOn the Valeant Pharma (NYSE: VRX) call, Bill Ackman said Valeant worth $180-$240 and worth $262-$350 longer term (2020).
... MoreEvercore ISI's Raffat Provides Thoughts on Valeant Pharma (VRX)
October 30, 2015 8:14 AM EDTEvercore ISI's Umer Raffat weighed in on Valeant Pharma (NYSE: VRX) following press reports last night on Philidor's drug dispensing practices and news this morning that Valeant is severing all ties to Philidor is a step in the right direction.
Raffat said he... More
Valeant Pharma (VRX) to Sever Ties with Philidor
October 30, 2015 5:59 AM EDTValeant Pharma (NYSE: VRX) announced that it is severing all ties with Philidor Rx Services, LLC, and that Philidor has informed Valeant that it will shut down operations as soon as possible, consistent with applicable laws.
"The newest allegations about activities at Philidor raise additional questions about the company's business practices," said J. Michael Pearson, Valeant's... More
